Vyro Bio

São Paulo, Brazil

Vyro develops oncolytic viruses designed to target CNS tumors, based on pioneering research on the oncolytic properties of the Zika Virus.

$200K raised

Jan 2025

Seed

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Vyro Bio raised?

Vyro Bio has raised $200K in total funding. The most recent round was Seed. The last funding was announced in January 2025.

Who are Vyro Bio's investors?

Vyro Bio's investors include Vesper Ventures SA.

Where is Vyro Bio headquartered?

Vyro Bio is headquartered in São Paulo, Brazil.

What does Vyro Bio do?

Vyro develops oncolytic viruses designed to target CNS tumors, based on pioneering research on the oncolytic properties of the Zika Virus.

What stage is Vyro Bio at?

Vyro Bio is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 1, 2025.

MLA

"Vyro Bio — Funding & Investors." VCBacked, January 1, 2025, https://www.vcbacked.co/company/vyro-bio. Accessed July 1, 2026.

APA

VCBacked. (2025). Vyro Bio — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/vyro-bio

Wikipedia (cite web)

{{cite web |title=Vyro Bio — Funding & Investors |url=https://www.vcbacked.co/company/vyro-bio |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 1, 2025.